Journal of Clinical Oncology, Vol 22, No 11 (June 1), 2004: pp. 2101-2107
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.11.044
Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study
Sanjiv S. Agarwala,
John M. Kirkwood,
Martin Gore,
Brigitte Dreno,
Nicholas Thatcher,
Beate Czarnetski,
Michael Atkins,
Antonio Buzaid,
Dimosthenis Skarlos,
Elaine M. Rankin
From the University of Pittsburgh Cancer Institute, Pittsburgh, PA; the Royal Marsden, National Health Service Trust, London, and Christie Hospital, National Health Service Trust, Withington, Manchester, United Kingdom; Clinique Dermatologique, Nantes Cedex, France; Virchow Klinikum, Universitat zu Berlin, Berlin, Germany; New England Medical Center, Boston, MA; Hospital Sirio-Libanês, São Paulo, Brazil; Agioi Anarguroi Hospital, Athens, Greece; and Netherlands Cancer Institute, Amsterdam, the Netherlands
Address reprint requests to Sanjiv S. Agarwala, MD, Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232; e-mail: agarwalass{at}msx.upmc.edu
PURPOSE: Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS. A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy.
PATIENTS AND METHODS: Eligible patients had histologically confirmed MM to the brain, and no prior radiotherapy or radiosurgery for brain metastases. Previously untreated patients received temozolomide at 200 mg/m2/d x 5 days; previously treated patients received 150 mg/m2/d x 5 days every 28 days. Treatment continued for 1 year or until disease progression or unacceptable toxicity.
RESULTS: Of 151 patients enrolled, 117 had received no prior systemic chemotherapy, and 34 had received prior chemotherapy for MM. Among previously untreated patients, 25% had more than four brain lesions, eight (7%) achieved an objective response (one complete and seven partial), and 34 (29%) had stable disease in brain metastases. Median overall survival was 3.5 months. Among previously treated patients, 21% had more than four brain lesions, one had a partial response, and six (18%) had stable disease in brain metastases. Median overall survival was 2.2 months. Temozolomide was well tolerated, with four (3%) patients discontinuing because of adverse events. Grade 3/4 hematologic toxicities included thrombocytopenia (3%), neutropenia (2%), and leukopenia (1%). Headache (9%) and vomiting (8%) were the most common nonhematologic grade 3/4 adverse events.
CONCLUSION: Temozolomide was well tolerated and demonstrated activity in the treatment of brain metastases from MM. Further evaluation of temozolomide combination therapy is warranted.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. POWELL and A. Z. DUDEK
Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases
Anticancer Res,
October 1, 2009;
29(10):
4189 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Siena, L. Crino, M. Danova, S. Del Prete, S. Cascinu, S. Salvagni, I. Schiavetto, M. Vitali, and E. Bajetta
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
Ann. Onc.,
September 18, 2009;
(2009)
mdp343v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Raizer, W.-J. Hwu, K. S. Panageas, A. Wilton, D. E. Baldwin, E. Bailey, C. von Althann, L. A. Lamb, G. Alvarado, M. H. Bilsky, et al.
Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features
Neuro-oncol,
April 1, 2008;
10(2):
199 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fontijn, A. D. Adema, K. K. Bhakat, H. M. Pinedo, G. J. Peters, and E. Boven
O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells
Mol. Cancer Ther.,
October 1, 2007;
6(10):
2807 - 2815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Quirt, S. Verma, T. Petrella, K. Bak, and M. Charette
Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review
Oncologist,
September 1, 2007;
12(9):
1114 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Eichler and J. S. Loeffler
Multidisciplinary Management of Brain Metastases
Oncologist,
July 1, 2007;
12(7):
884 - 898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Gerstner and R. L. Fine
Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm
J. Clin. Oncol.,
June 1, 2007;
25(16):
2306 - 2312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Schadendorf, A Hauschild, S Ugurel, A Thoelke, F Egberts, M Kreissig, R Linse, U Trefzer, T Vogt, W Tilgen, et al.
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann. Onc.,
October 1, 2006;
17(10):
1592 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Fine, J. Chen, C. Balmaceda, J. N. Bruce, M. Huang, M. Desai, M. B. Sisti, G. M. McKhann, R. R. Goodman, J. S. Bertino Jr., et al.
Randomized study of Paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5770 - 5776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Khuntia, P. Brown, J. Li, and M. P. Mehta
Whole-Brain Radiotherapy in the Management of Brain Metastasis
J. Clin. Oncol.,
March 10, 2006;
24(8):
1295 - 1304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al.
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Mol. Cancer Ther.,
March 1, 2006;
5(3):
732 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kaufmann, K. Spieth, U. Leiter, C. Mauch, P. von den Driesch, T. Vogt, R. Linse, W. Tilgen, D. Schadendorf, J. C. Becker, et al.
Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group
J. Clin. Oncol.,
December 10, 2005;
23(35):
9001 - 9007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Weber, S. O'Day, M. Rose, R. Deck, P. Ames, J. Good, J. Meyer, R. Allen, S. Trautvetter, M. Timmerman, et al.
Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-{alpha}2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma
J. Clin. Oncol.,
December 10, 2005;
23(35):
8992 - 9000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bottoni, P. Bonaccorsi, V. Devirgiliis, V. Panasiti, R. G. Borroni, G. Trasimeni, R. Clerico, and S. Calvieri
Complete Remission of Brain Metastases in Three Patients with Stage IV Melanoma Treated with BOLD and G-CSF
Jpn. J. Clin. Oncol.,
September 1, 2005;
35(9):
507 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
Clin. Cancer Res.,
June 1, 2005;
11(11):
3987 - 4002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Legha
Treatment of Brain Metastases From Melanoma
J. Clin. Oncol.,
May 1, 2005;
23(13):
3155 - 3155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Agarwala
In Reply:
J. Clin. Oncol.,
May 1, 2005;
23(13):
3155 - 3156.
[Full Text]
[PDF]
|
|
|
|
